Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma

🔗 Access full article via ACS Cancer

Chromosome 1 abnormalities in multiple myeloma (MM) are increasingly recognized as high risk-defining features . Presence of del(1p13.3) confers inferior progression-free survival (PFS) and overall survival . On multivariate analysis, the presence of ISS stage 3 disease, GEP70 HR, 1q21 gain or amp were independent predictors of PFS or OS .